This segment focuses on the research, development, and commercialization of therapies for Pulmonary Arterial Hypertension (PAH), a rare and life-threatening cardiopulmonary disease. Liquidia's primary product candidate in this area is LIQ861, an inhaled dry powder formulation of treprostinil, designed to improve the delivery and efficacy of the drug. Research and development activities include clinical trials, formulation optimization, and manufacturing process improvements. The company utilizes its proprietary PRINT technology to engineer drug particles for enhanced lung delivery. The patient impact is significant, as PAH patients often face debilitating symptoms and limited treatment options. Liquidia aims to provide a more convenient and effective inhaled treprostinil therapy, potentially improving patient outcomes and quality of life. Market positioning involves competing with existing PAH treatments while offering a differentiated product with improved delivery. Future opportunities include expanding the PAH product portfolio and exploring applications of PRINT technology in other respiratory diseases. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations include collaborations with Pharmosa Biopharm for the development of sustained-release inhaled Treprostinil product in North America.

This segment focuses on the development of sustained-release formulations for pain management, specifically targeting post-operative pain. The primary product candidate is LIQ865, a sustained-release formulation of bupivacaine. Research and development activities include formulation development, preclinical studies, and clinical trials to assess the safety and efficacy of LIQ865. The company utilizes its PRINT technology to create controlled-release drug particles. The therapeutic area is local post-operative pain, addressing the significant unmet need for effective and long-lasting pain relief after surgery. Patient impact includes reduced pain, improved recovery, and decreased reliance on opioid medications. Market positioning involves competing with existing pain management options while offering a potentially superior sustained-release formulation. Future opportunities include expanding the pain management product portfolio and exploring applications of PRINT technology in other pain indications. Regulatory and clinical aspects involve obtaining FDA approval and conducting clinical trials to demonstrate safety and efficacy. This segment may involve partnerships with pharmaceutical companies for commercialization and distribution.

This segment involves the distribution of generic treprostinil injection in the United States. The company sources and distributes this product to meet the needs of patients requiring this medication. Activities include supply chain management, quality control, and sales and marketing efforts. The therapeutic area is pulmonary hypertension, providing an alternative treatment option for patients. Patient impact includes ensuring access to an essential medication for managing PAH. Market positioning involves competing with other generic treprostinil suppliers. Future opportunities include expanding the distribution network and exploring opportunities to offer additional generic products. Regulatory and clinical aspects involve compliance with FDA regulations and ensuring product quality. This segment may involve partnerships with distributors and healthcare providers.